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Multidrug-resistant (MDR) Klebsiella pneumoniaemay require combination therapy. We systematically investigated bacterial
killing with colistin and doripenemmono- and combination therapy against MDR K. pneumoniae and emergence of colistin
resistance. A one-compartment in vitro pharmacokinetic/pharmacodynamic model was employed over a 72-h period with two
inocula (106 and108 CFU/ml); a colistin-heteroresistant reference strain (ATCC 13883) and three clinical isolates (colistin-
susceptible FADDI-KP032 [doripenem resistant], colistin-heteroresistant FADDI-KP033, and colistin-resistant FADDI-KP035)
were included. Four combinations utilizing clinically achievable concentrations were investigated. Microbiological responses
were examined by determining log changes and population analysis profiles (for emergence of colistin resistance) over 72 h.
Against colistin-susceptible and -heteroresistant isolates, combinations of colistin (constant concentration regimens of 0.5 or 2
mg/liter) plus doripenem (steady-state peak concentration [Cmax] of 2.5 or 25 mg/liter over 8 h; half-life, 1.5 h) generally resulted
in substantial improvements in bacterial killing at both inocula. Combinations were additive or synergistic against ATCC 13883,
FADDI-KP032, and FADDI-KP033 in 9, 9, and 14 of 16 cases (4 combinations at 6, 24, 48, and 72 h) at the 106-CFU/ml inoculum
and 14, 11, and 12 of 16 cases at the 108-CFU/ml inoculum, respectively. Combinations at the highest dosage regimens resulted in
undetectable bacterial counts at 72 h in 5 of 8 cases (4 isolates at 2 inocula). Emergence of colistin-resistant subpopulations in
colistin-susceptible and -heteroresistant isolates was virtually eliminated with combination therapy. Against the colistin-resis-
tant isolate, colistin at 2 mg/liter plus doripenem (Cmax, 25 mg/liter) at the low inoculum improved bacterial killing. This investi-
gation provides important information for optimization of colistin-doripenem combinations.
The emergence of nosocomial Klebsiella pneumoniae resistantto almost all available antibiotics, including carbapenems, is
an increasing problem worldwide (7, 18, 21, 22, 27, 38). Increasing
resistance combined with a lack of novel antibiotics in the drug
discovery pipeline for Gram-negative pathogens (7) has forced a
reevaluation of “old” antibiotics, in particular colistin (polymyxin
E), which retains activity against many of these multidrug-resis-
tant (MDR) Gram-negative organisms (24, 30, 31, 33). As a
consequence, the use of colistin has increased substantially
over the past few years, particularly for critically ill patients.
However, colistin-resistant K. pneumoniae has rapidly emerged
(1, 6, 26, 35, 48).
Colistin is administered parenterally in the form of its sulfo-
methyl derivative, sodium colistin methanesulfonate (CMS). The
inactive prodrug CMS undergoes conversion in vivo to the active
species, colistin (4, 17, 43). Although CMS has been available in
the clinic for more than 50 years, only recently has reliable infor-
mation on the pharmacokinetics (PK) and pharmacodynamics
(PD) of CMS and formed colistin emerged. It is evident from these
investigations that the plasma colistin concentrations achieved in
critically ill patients with currently recommended CMS dosage
regimens are low and in many cases suboptimal (17, 43). Unfor-
tunately, colistin-induced nephrotoxicity is a dose-limiting ad-
verse effect in up to 50% of patients (11, 17, 19, 28), and thus
increasing the daily dose may not be an acceptable option (17).
Further complicating the use of CMS as monotherapy is the phe-
nomenon of colistin heteroresistance, the presence of colistin-
resistant subpopulations within an isolate that is susceptible based
upon its MIC. Colistin heteroresistance, which has been identified
in K. pneumoniae (37, 44), Acinetobacter baumannii (20, 32, 51),
and Pseudomonas aeruginosa (3), is thought to contribute to the
rapid emergence of colistin resistance observed with mono-
therapy. Collectively, these observations suggest caution with the
use of colistin monotherapy and have led some to propose that
colistin may be best used as part of combination therapy (17, 40).
The aim of the present study was to systematically investigate us-
ing a range of isolates the extent of in vitro bacterial killing and the
emergence of colistin resistance ofK. pneumoniae, at both low and
high inocula, using clinically relevant dosage regimens of colistin
alone and in combination with doripenem.
(Parts of this study were presented at the 51st Annual Inter-
science Conference on Antimicrobial Agents and Chemotherapy
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(ICAAC), Chicago, IL, 17 to 20 September 2011, and the 22nd
European Congress of Clinical Microbiology and Infectious Dis-
eases (ECCMID), London, United Kingdom, 31 March to 3 April
2012.)
MATERIALS AND METHODS
Bacterial isolates. K. pneumoniae ATCC 13883 (American Type Culture
Collection, Rockville, MD) and three clinical isolates (FADDI-KP032,
FADDI-KP033, and FADDI-KP035) were selected based upon differing
patterns of susceptibility to colistin and doripenem and included colistin-
heteroresistant strains (Table 1); the method of determining colistin het-
eroresistance is described below. FADDI-KP033 and FADDI-KP032 were
kindly donated by Ben Howden (Austin Hospital, Melbourne, Australia)
and were taken from the same patient before and after carbapenem ther-
apy, whereas FADDI-KP035 was from Diagnostic Services of Manitoba
(Health Sciences Centre, Winnipeg, Canada). All clinical strains in this
study fulfilled the definition of MDR of the Centers for Disease Control
and Prevention (45).
MICs of colistin and doripenem were determined for each isolate in
two replicates on separate days in cation-adjusted Mueller-Hinton broth
(CAMHB) (containing 23.0 mg/liter Ca2 and 11.5 mg/liter Mg2
[Oxoid, Hampshire, England]) via broth microdilution (15); European
Committee on Antimicrobial Susceptibility Testing (EUCAST) (Växjö,
Sweden) breakpoints against the Enterobacteriaceae were employed (Ta-
ble 1) (14). All isolates produced -lactamases, although only FADDI-
KP032 was resistant to doripenem based upon MICs (Table 1). Isolates
were stored in tryptone soy broth (Oxoid, Basingstoke, Hampshire, Eng-
land) with 20% glycerol (Ajax Finechem, Seven Hills, NSW, Australia) at
80°C.
Antibiotics. For MIC determinations and in vitro PK/PD studies,
colistin sulfate (lot 070M1499V; 23,690 U/mg) was purchased from Sig-
ma-Aldrich (St. Louis, MO), while doripenem (lot 9GBSE00) was from
Janssen-Cilag (Australia). Colistin sulfate was employed in the current
study because colistin is the active antibacterial agent formed in vivo fol-
lowing administration of CMS (4). Colistin was prepared using Milli-Q
water (Millipore Australia, North Ryde, New South Wales, Australia) at
the beginning of each experiment and spiked into the sterile broth that
was pumped into the central reservoir (see below) to achieve the desired
concentration; we have previously shown that colistin is stable under
these conditions for the duration of the experiment (5). Stock solutions of
doripenem were similarly prepared using 0.9% sodium chloride immedi-
ately prior to each administration to the PK/PD model, protected from
light to minimize loss from degradation, and sterilized by filtration with a
0.22-m Millex-GP filter (Millipore, Bedford, MA). Concentrations of
colistin and doripenem in the reservoirs were measured using high-per-
formance liquid chromatography as described previously (5, 29).
In vitro pharmacokinetic/pharmacodynamic model. A one-com-
partment in vitro PK/PD model was used to examine the microbiological
response and emergence of resistance to various dosage regimens of colis-
tin and doripenem alone and in combination over 72 h at two different
starting inocula (106 and108 CFU/ml) (5). All drug-containing regi-
mens (whether mono- or combination therapy) mimicked the PK profiles
of each drug achieved in critically ill patients (17, 39, 43). Since we have
previously demonstrated that both colistin (2) and doripenem (5) are
almost entirely unbound in CAMHB, the specified concentrations repre-
sent unbound (free) concentrations. Colistin (when included in the dos-
age regimen) was delivered at a clinically relevant concentration (Table 2)
to mimic the flat colistin concentration-versus-time profiles observed
across a dosage interval at steady state in patients receiving short-term
infusions of CMS intravenously (i.v.) every 8 to 24 h (17, 43); since colistin
was added to all media prior to each experiment, steady-state concentra-
tions were present from the beginning of each experiment. For dorip-
enem-containing regimens, doripenem was injected as a bolus dose into
each treatment compartment following bacterial inoculation to achieve
the desired steady-state peak concentration (Cmax), with intermittent dos-
ing every 8 h thereafter (Table 2); no loading dose of doripenem was
required to achieve steady-state concentrations, since doripenem does not
accumulate with intermittent i.v. administration. The flow rate of sterile
media through the system simulated a doripenem elimination half-life
(t1/2) of 1.5 h, which approximates that in critically ill patients (36). Three
monotherapy dosage regimens (each) were simulated for colistin and
doripenem (for the colistin-resistant isolate, only colistin at 5 mg/liter was
used), with four colistin-doripenem regimens used for combination ther-
apy (Table 2).
Microbiological response and emergence of resistance to colistin.
Serial samples (1 ml) were collected aseptically from the central reservoir
of the PK/PD model at the times shown in Table 2 for determination of
colistin and doripenem concentrations, as well as viable cell counting and
real-time population analysis profiles (PAPs) (5). Viable counting and
PAPs were conducted immediately after sampling by spiral plating
(WASP2 spiral plater; Don Whitley Scientific Ltd., United Kingdom) 50
l of sample (appropriately diluted with 0.9% saline) on either nutrient
agar (viable counting) or Mueller-Hinton agar (PAPs), followed by incu-
bation for 24 h (48 h for plates with small colonies) at 35°C. The limit of
detection was 20 CFU/ml (equivalent to 1 colony per plate), whereas the
limit of quantification was 400 CFU/ml (equivalent to 20 colonies per
plate). Colistin heteroresistance was defined as a colistin-susceptible iso-
late (i.e., MIC 2 mg/liter) in which subpopulations were able to grow in
the presence of2 mg/liter colistin in the PAPs (44).
PD analysis. The log change method comparing the change in log10
(CFU/ml) from 0 h (CFU0) to time t (6, 24, 48, or 72 h; CFUt), calculated
as log change log10 CFUt log10 CFU0, was used to examine microbi-
ological responses to monotherapy and combination therapy. Single-an-
tibiotic or combination regimens causing a reduction of1 log10 CFU/ml
below the initial inoculum at the specified time were considered active.
Synergy was defined as 2-log10 killing for the combination relative to
that for its most active component at the specified time; additivity was
defined as a 1- to2-log10 superior killing for the combination (42).
RESULTS
PK validation. The colistin concentrations achieved (mean 	
standard deviation [SD]) were 0.48	 0.13 mg/liter (n 40), 1.92	
0.35 mg/liter (n 46), and 5.11	 0.83 mg/liter (n 19) for the
targeted concentrations of 0.50, 2.00, and 5.00 mg/liter, respec-
tively. The measured doripenem Cmax was 2.84 	 0.41 mg/liter
(n  52) for the targeted value of 2.50 mg/liter, 24.5 	 2.78 mg/
liter (n  56) for the targeted value of 25.0 mg/liter, and 49.0 	
4.06 mg/liter (n 17) mg/liter for the targeted value of 50.0 mg/
liter.
TABLE 1 MICs for K. pneumoniae isolates used in this studya
Isolate
MIC (mg/liter)b
-Lactamase
typingc
Colistin
heteroresistantdColistin Doripenem
ATCC 13883 1 0.125 SHV Yes
FADDI-KP033e 1 0.125 SHV and DHA Yes
FADDI-KP032e 1 8 SHV and DHA No
FADDI-KP035 128 0.125 SHV NA
a All clinical isolates were MDR according to the definition of the Centers for Disease
Control and Prevention (45).
b EUCAST breakpoints for colistin are2 mg/liter for susceptibility and2 mg/liter
for resistance. For doripenem, the breakpoints are1 mg/liter for susceptibility and4
mg/liter for resistance (14).
c The strain contains genes encoding SHV class A and/or DHA AmpC type -lactamase.
d Heteroresistance to colistin was defined as the existence, in an isolate for which the
colistin MIC was2 mg/liter, of subpopulations able to grow in the presence of2
mg/liter colistin (44). NA, not applicable due to colistin resistance.
e FADDI-KP033 and FADDI-KP032 were taken from the same patient before and after
carbapenem therapy (isolates 16 and 17 from a previous study [44]).
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Microbiological response. For the targeted inoculum of106
CFU/ml, initial log10 CFU/ml (mean	 SD) were 6.21	 0.19 (n
11), 6.54	 0.25 (n 11), 6.48	 0.19 (n 11), and 6.56	 0.18
(n  9) for ATCC 13883, FADDI-KP033, FADDI-KP032, and
FADDI-KP035, respectively; the corresponding values for the tar-
geted inoculum of108 CFU/ml were 8.17	 0.15 (n 11), 7.94	
0.08 (n 11), 8.28	 0.13 (n 11), and 8.31	 0.16 (n 8) log10
CFU/ml. The colistin PAPs conducted at baseline at an inoculum
of 108 CFU/ml revealed the presence of preexisting colistin-
resistant subpopulations (i.e., colistin heteroresistance) in some
isolates (Fig. 1, baseline). The time course profiles of bacterial
numbers achieved with all dosage regimens for each of the four
isolates at both inocula are shown in Fig. 1 and 2. Log changes in
viable cell counts at each inoculum with mono- and combination
therapy are presented in Table 3.
Colistin monotherapy. At the 106-CFU/ml inoculum, colistin
monotherapy regimens (a constant concentration of 0.5, 2, or 5
mg/liter) against the colistin-susceptible and -heteroresistant iso-
lates produced rapid and extensive initial killing to 2-log10
CFU/ml or below (Fig. 1). For the colistin-susceptible isolate
KP032 and the heteroresistant clinical isolate KP033, no viable
bacteria were detected by 1 to 2 h with colistin at 2 and 5 mg/liter
(and colistin at 0.5 mg/liter for KP033). For KP032, regrowth
equivalent to that of the control occurred by 48 h with colistin at
0.5 mg/liter, whereas regrowth with the higher colistin concentra-
tion regimens was substantially reduced across the 72 h. For both
heteroresistant strains, regrowth approaching that of the control
occurred by 24 to 48 h with all colistin regimens (0.5, 2, and 5
mg/liter). An inoculum effect with colistin monotherapy was ev-
ident. At the 108-CFU/ml inoculum, colistin at 0.5 and 2 mg/liter
produced virtually no bacterial killing at any time against the
colistin-susceptible or -heteroresistant strains. Although colistin
at 5 mg/liter produced rapid and extensive initial killing (5- to
6-log10 CFU/ml) against these isolates, regrowth was evident by 4
to 6 h, and bacterial counts had returned close to control values by
24 h in all cases (Fig. 2). Against the colistin-resistant isolate
KP035, bacterial growth in the presence of colistin at 5 mg/liter
was essentially no different from that of the growth control at
either inoculum (Fig. 2).
Doripenem monotherapy. For doripenem-susceptible iso-
lates at the 106-CFU/ml inoculum, all doripenem regimens (Cmax
of 2.5, 25, or 50 mg/liter) produced rapid initial bacterial killing by
3-log10 CFU/ml. For ATCC 13883, with a doripenem Cmax of
2.5 mg/liter, regrowth had begun by 6 h, and bacterial numbers
remained3-log10 CFU/ml below control values across the 72 h
(Fig. 1); regrowth with doripenem Cmax values of 25 and 50 mg/
liter was greatly suppressed for this strain, with no viable bacteria
detected from 48 h onwards. For the remaining two doripenem-
susceptible isolates, regrowth with doripenem Cmax values of 2.5
and 25 mg/liter was evident by 8 h and was within1- to 3-log10
CFU/ml of control values by 72 h. With the highest doripenem
dosage regimen (Cmax of 50 mg/liter), no viable bacteria were de-
tected by 2 to 6 h, although substantial regrowth beginning at 24 h
occurred for KP035; for KP033, no viable bacteria were detected
after 2 h. For the doripenem-resistant isolate (KP032), doripenem
Cmax values of 25 and 50 mg/liter each produced substantial early
bacterial killing despite a doripenem MIC of 8 mg/liter, with re-
growth to2-log10 CFU/ml by 72 h; bacterial growth in the pres-
TABLE 2 Colistin and doripenem dosage regimens, PK/PD index values, and sampling times in the in vitro PK/PD modela
Treatment regimen
PK/PD index valueb
Sampling times (h)
for microbiological
measurementsƒ
ƒAUC/MIC ƒCmax/MIC ƒTMIC
ATCC
13883
FADDI-
KP033
FADDI-
KP032
FADDI-
KP035
ATCC
13883
FADDI-
KP033
FADDI-
KP032
FADDI-
KP035
ATCC
13883
FADDI-
KP033
FADDI-
KP032
FADDI-
KP035
Col monotherapy,c target
concn (mg/liter)
0, 1, 2, 3, 4, 6, 8, 24,
26, 28, 48, 50,
52, 72
0.5 12.0 12.0 12.0 0.09 0.50 0.50 0.50 0.004 0 0 0 0
2.0 48.0 48.0 48.0 0.38 2.0 2.0 2.0 0.016 100 100 100 0
5.0 120.0 120.0 120.0 0.94 5.0 5.0 5.0 0.039 100 100 100 0
Dor monotherapy,d target
Cmax/Cmin
(mg/liter)
0, 1, 2, 3, 4, 6, 8, 24,
26, 28, 48, 50,
52, 72
2.5/0.062 127 127 1.98 127 20 20 0.32 20 81.0 81.0 0 81.0
25/0.62 1,266 1,266 19.8 1,266 200 200 3.13 200 100 100 30.8 100
50/1.24 2,532 2,532 39.6 2,532 400 400 6.25 400 100 100 49.6 100
Combination therapye 0, 1, 2, 3, 4, 6, 8, 24,
26, 28, 48, 50,
52, 72
a Dosage regimens were tested with106- and108-CFU/ml starting inocula.
b Values shown are target values for PK/PD indices. For combination therapy, the PK/PD indices for each drug were the same as those for equivalent monotherapy. ƒAUC/MIC,
area under the unbound drug concentration-time curve over 24 h in the steady state divided by the MIC; ƒCmax/MIC, unbound drug maximal concentration divided by the MIC;
ƒTMIC, cumulative percentage of a 24-h period that the unbound drug concentration exceeds the MIC under steady-state PK conditions.
c Colistin (Col) dosage regimens involved a constant concentration of colistin simulating the flat colistin concentration-versus-time profiles observed across a dosing interval at
steady state in patients receiving short-term infusions of CMS i.v. every 8 to 24 h. For the colistin-resistant isolate (FADDI-KP035), only colistin at 5 mg/liter was used as
monotherapy. Values shown for isolate FADDI-KP035 at other dosages of colistin are those for combination therapy with the indicated dosage regimen of colistin.
d Doripenem (Dor) dosage regimens involved intermittent administration (every 8 h) to achieve the targeted Cmax and Cmin.
e Combination therapy was carried out with the following dosage regimens: colistin at 0.5 mg/liter plus a doripenem Cmax of 2.5 mg/liter, colistin at 0.5 mg/liter plus a doripenem
Cmax of 25 mg/liter, colistin at 2 mg/liter plus a doripenem Cmax of 2.5 mg/liter, and colistin at 2 mg/liter plus a doripenem Cmax of 25 mg/liter.
ƒ The number of CFU/ml was determined at all time points. Full PAPs were generated at 0 and 72 h; mini-PAPs were generated at 6, 24, and 48 h.
Use of Colistin and Doripenem against K. pneumoniae
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ence of a doripenem Cmax of 2.5 mg/liter was essentially no differ-
ent from that of the growth control. An inoculum effect was
generally observed with monotherapy against doripenem-suscep-
tible isolates.
Combination therapy. For the colistin-susceptible isolate
KP032, the addition of doripenem at aCmax of 2.5 or 25 mg/liter to
colistin at 0.5 mg/liter at the low inoculum produced1.5-log10-
greater initial killing than monotherapy, with no viable bacteria
detected from 2 to 4 h; both combinations resulted in synergy at
virtually all time points across 72 h. Improved activity was partic-
ularly noticeable with the combination of colistin at 0.5 mg/liter
and doripenem at 2.5 mg/liter, which produced 4- to 5-log10-
greater killing than monotherapy at 48 and 72 h. There was no
enhancement of bacterial activity at this inoculum with combina-
tions containing colistin at 2 mg/liter, with similarly large activity
compared to that in the presence of equivalent colistin mono-
therapy (Fig. 1C and Table 3). At the 108-CFU/ml inoculum, bac-
terial killing was not improved when colistin and doripenem were
combined in the lowest-dosage regimens (constant 0.5 mg/liter of
colistin and a doripenem Cmax of 2.5 mg/liter); however, all other
combinations resulted in substantially greater activity with syner-
gistic (predominantly) or additive effects at nearly all time points
(Fig. 2C and Table 3). Combinations with colistin at 0.5 or 2 mg/
liter plus a doripenem Cmax of 25 mg/liter were particularly active
and produced5- to 7-log10-greater killing than the most active
monotherapy (doripenem) at 48 and 72 h, with no viable colonies
detected across the 72-h period on at least one occasion.
Against both colistin-heteroresistant strains, bacterial killing
was substantially enhanced at most time points across 72 h with
most combinations at both inocula (Fig. 1 and 2 and Table 3). For
FIG 1 (Left) Time-kill curves with various clinically relevant dosage regimens of colistin (Col) and doripenem (Dor) alone and in combination at an inoculum
of106 CFU/ml. (Right) PAPs at baseline and after 72 h of exposure to colistin monotherapy, colistin-doripenem combination therapy, or neither antibiotic
(growth control). Doripenem monotherapy regimens were not included in colistin-PAP examination. (A) ATCC 13883 (colistin heteroresistant, doripenem
susceptible, MDR); (B) FADDI-KP033 (colistin heteroresistant, doripenem susceptible, MDR); (C) FADDI-KP032 (colistin susceptible, doripenem resistant,
MDR); (D) FADDI-KP035 (colistin resistant, doripenem susceptible, MDR). The y axis starts at the limit of detection, and the limit of quantification is indicated
by the dashed horizontal line.
TABLE 3 Log changes in numbers of CFUa
a Log changes at 6, 24, 48, and 72 h at an inoculum of 106 or 108 CFU/ml with colistin (Col) and/or doripenem (Dor) against four K. pneumoniae isolates. The gray background
indicates activity (a reduction of1-log10 CFU/ml below the initial inoculum); the green background indicates synergy (a2-log10 decrease in the number of CFU/ml between the
combination and its most active component); the red background indicates additivity (a 1.0- to2-log10 decrease in the number of CFU/ml between the combination and its most
active component). NA, not available.
b Colistin-resistant isolate; colistin monotherapy performed with 5 mg/liter only. The calculations of synergy/additivity were based on colistin at 5 mg/liter.
Use of Colistin and Doripenem against K. pneumoniae
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clinical isolate KP033 at the low inoculum, combinations contain-
ing a doripenem Cmax of 2.5 mg/liter with colistin (0.5 or 2 mg/
liter) generally resulted in4- to 5-log10 greater killing across 24
to 72 h compared to results with monotherapy, whereas both
combinations containing a doripenem Cmax of 25 mg/liter gener-
ally resulted in 2- to 3-log10 greater killing across the same pe-
riod; all combinations resulted in sustained periods where no vi-
able bacteria were detected. Of the 12 cases from 24 to 72 h (i.e., 4
combinations across 3 time points), 11 were synergistic, with the
remaining case being additive (Fig. 1B and Table 3). Though ac-
tivity was reduced somewhat at the higher inoculum with combi-
nations containing a doripenem Cmax of 2.5 mg/liter, both com-
binations containing a doripenem Cmax of 25 mg/liter
substantially increased activity and resulted in 5- to 7-log10-
greater killing at most time points across 24 to 72 h (Fig. 2B and
Table 3). The latter combinations resulted in undetectable bacte-
rial counts on at least two occasions and, for the combination of
colistin at 2 mg/liter plus a doripenem Cmax of 25 mg/liter, no
viable bacteria from 48 h onwards. Bacterial killing was similarly
enhanced for reference strain ATCC 13883. Although the combi-
nations of colistin at 0.5 or 2 mg/liter plus a doripenem Cmax of 25
mg/liter failed to substantially improve activity at the low inocu-
lum (owing to the potent bacterial killing of equivalent doripenem
monotherapy), the remaining two combinations at the low inoc-
ulum and all combinations at the high inoculum substantially
increased bacterial killing over the corresponding monotherapy.
Notably, at the high inoculum, all combinations produced bacte-
rial killing to below the limit of detection by 26 to 28 h (3- to
4-log10-greater killing than with doripenem monotherapy with a
Cmax of 25 mg/liter), with no viable bacteria detected after this
time for all combinations except that of colistin at 0.5 mg/liter plus
a doripenem Cmax of 2.5 mg/liter; with the latter combination,
regrowth to 2-log10 CFU/ml occurred by 72 h, which was 3-
log10 CFU/ml lower than that with the most active equivalent
monotherapy (doripenem).
For colistin-resistant isolate KP035 at the 106-CFU/ml inocu-
lum, only the combination of colistin at 2 mg/liter plus a dorip-
enem Cmax of 25 mg/liter resulted in enhanced bacterial killing.
This combination provided additional killing of3- and 6.5-log10
CFU/ml at 24 and 72 h, respectively, over that achieved with
doripenem monotherapy; from 50 h onwards, no viable bacteria
were detected with this combination (Fig. 1D and Table 3). At the
high inoculum, bacterial killing and regrowth with combination
therapy were very similar to those produced with equivalent
doripenem monotherapy (Fig. 2D and Table 3).
Emergence of colistin resistance. Apart from a small shift to
the right at the 106-CFU/ml inoculum, PAPs for the growth con-
trols at 72 h were generally similar to those observed at baseline.
For the colistin-susceptible isolate (KP032), monotherapy with
colistin at 0.5 mg/liter at the 106 CFU/ml inoculum resulted in an
increase in colistin-resistant subpopulations by 24 h, growing in
the presence of colistin at 10 mg/liter at 72 h; with higher colistin
regimens (2 and 5 mg/liter), the low regrowth observed across 72
h at this inoculum precludes meaningful interpretation of the
PAPs (Fig. 1C). At the high inoculum, a small number of resistant
colonies emerged by 24 h with the colistin 0.5-mg/liter regimen,
with the proportion of resistant colonies remaining approxi-
mately the same up to 72 h. At this inoculum, the colistin 5-mg/
liter regimen resulted in a rapid and substantial increase in colis-
tin-resistant colonies such that by 24 h, virtually all colonies grew
in the presence of colistin at 10 mg/liter; the colistin 2-mg/liter
regimen led to a slower but substantial emergence of colistin-
resistant subpopulations across 72 h (Fig. 2C). For the two hetero-
resistant strains, all colistin monotherapy regimens (0.5, 2, and 5
mg/liter) resulted in substantial increases in colistin-resistant sub-
populations by 24 to 48 h. At the 106-CFU/ml inoculum, all colis-
tin regimens led to emergence of resistance, with growth in the
presence of 8 or 10 mg/liter colistin by 24 to 48 h (data not shown);
at the high inoculum, all regimens resulted in a substantial in-
crease in resistant subpopulations with colistin at 5 mg/liter at 72
h, resulting in nearly all subpopulations growing in the presence of
colistin at 10 mg/liter on the PAP plates (Fig. 2A and B). For the
colistin-resistant isolate KP035, the PAPs at baseline and across
the 72-h incubation period did not change irrespective of inocu-
lum, with virtually all colonies in the control and treatment
groups growing in the presence of colistin at 10 mg/liter (Fig. 1D
and 2D).
Combination therapy against the colistin-susceptible isolate
KP032 resulted in the emergence of colistin-resistant subpopula-
tions only with the combination of colistin at 0.5 mg/liter plus a
doripenem Cmax of 2.5 mg/liter and only at the high inoculum
(Fig. 2C). Although many combinations at both inocula resulted
in substantial bacterial killing, for KP032 no colistin-resistant col-
onies were detected at any time with the combination of colistin at
2 mg/liter and a doripenemCmax of 2.5 mg/liter at the 10
8-CFU/ml
inoculum despite substantial regrowth (to 6-log10 CFU/ml) at
72 h (Fig. 2C). For the colistin-heteroresistant strains, no colistin-
resistant colonies were detected following the initiation of combi-
nation therapy at any time at either inoculum, even on the few
occasions where regrowth was extensive, e.g., with isolate KP033
at the high inoculum, where regrowth to 7-log10 CFU/ml oc-
curred at 72 h with the combinations of colistin at 0.5 or 2 mg/liter
plus a doripenem Cmax of 2.5 mg/liter (Fig. 2B). Combination
therapy had no effect on colistin resistance of the MDR colistin-
resistant isolate.
DISCUSSION
With colistin (and polymyxin B) monotherapy, regrowth of K.
pneumoniae as well as other bacterial species considered suscepti-
ble to colistin based upon MIC measurement is well documented
both in vitro (3, 32, 44) and in vivo (25), even with concentrations
well in excess of those which can be safely achieved clinically.
Amplification of colistin-resistant subpopulations, which has
been shown to contribute to the observed regrowth, may be par-
FIG 2 (Left) Time-kill curves with various clinically relevant dosage regimens of colistin (Col) and doripenem (Dor) alone and in combination at an inoculum
of108 CFU/ml. (Right) PAPs at baseline and after 72 h of exposure to colistin monotherapy, colistin-doripenem combination therapy, or neither antibiotic
(growth control). Doripenem monotherapy regimens were not included in colistin-PAPs examination. (A) ATCC 13883 (colistin heteroresistant, doripenem
susceptible, MDR); (B) FADDI-KP033 (colistin heteroresistant, doripenem susceptible, MDR); (C) FADDI-KP032 (colistin susceptible, doripenem resistant,
MDR); (D) FADDI-KP035 (colistin resistant, doripenem susceptible, MDR). The y axis starts at the limit of detection, and the limit of quantification is indicated
by the dashed horizontal line.
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ticularly important forK. pneumoniae, which has a high frequency
of colistin heteroresistance (75% [37] and 90% [44] of isolates
in previous studies). With currently recommended CMS dosage
regimens achieving low colistin concentrations in plasma (17, 43)
and toxicity limiting dose escalation in many patients (11, 17),
CMS monotherapy may be suboptimal. Consequently, the inves-
tigation of rational colistin combinations is essential. We system-
atically investigated the effectiveness of colistin alone and in com-
bination with doripenem against a diverse array of K. pneumoniae
isolates which included colistin-susceptible, -heteroresistant, and
-resistant strains.
The dosage regimens of colistin and doripenem employed in
the present study were carefully designed to reflect the plasma
concentration-time profiles achieved in critically ill patients (17,
39, 43). Previously we have shown that both colistin and dorip-
enem are almost entirely unbound in CAMHB (2, 5). Currently,
there is no information on unbound plasma concentrations of
colistin in humans. However, assuming plasma binding of colistin
in patients is similar to that in animals (i.e., 50% bound) (29,
52), the colistin dosage regimens of 0.5 and 2 mg/liter used in our
combinations are indeed clinically achievable (17, 43). Colistin
was administered as a constant infusion to mimic the flat concen-
tration-versus-time profiles observed across a dosage interval at
steady state (17, 43). All doripenem dosage regimens employed in
the combinations are readily achieved in plasma after consider-
ation of protein binding (5). Considering the inoculum effect of
colistin and carbapenems (9, 10), experiments were conducted at
both 106 and 108 CFU/ml; the latter inoculum mimics the
high bacterial densities found in some infections (34, 47). In gen-
eral, the colistin-and-doripenem combination maintained its ex-
cellent activity at both inocula (Table 3) and was less subject to an
inoculum effect compared to monotherapy with either agent.
The PK/PD index that best predicts colistin activity against K.
pneumoniae is currently unknown. Against P. aeruginosa (2, 12)
and A. baumannii (13), area under the unbound drug concentra-
tion-time curve over 24 h in the steady state divided by the MIC
(fAUC/MIC) is the index for colistin most closely correlated with
bacterial killing. For P. aeruginosa, an fAUC/MIC of 20 was
required to achieve a 1-log reduction at 24 h against most isolates
(2, 12); this value was somewhat lower (10) for equivalent kill-
ing ofA. baumannii (13). If an fAUC/MIC target of20 is applied
to the present study, only the colistin 0.5-mg/liter regimen failed
to reach this value against colistin-susceptible and -heteroresis-
tant isolates (fAUC/MIC of 12), whereas all regimens were con-
siderably below a fAUC/MIC of 20 for the colistin-resistant isolate
(Table 2). However, even with a fAUC/MIC of 48 (colistin 2-mg/
liter regimen) or 120 (colistin 5-mg/liter regimen), monotherapy
with colistin reduced bacterial growth by1 log at 24 h only with
the 106-CFU/ml inoculum (in five of six cases; Table 3). The
PK/PD index most closely associated with doripenem activity
against Gram-negative bacilli is the cumulative percentage of a
24-h period that the unbound drug concentration exceeds the
MIC under steady-state PK conditions (ƒTMIC) (50). For dorip-
enem, an ƒTMIC of 35 to 45% is required for a1-log reduction
in bacterial growth (50). Against the doripenem-susceptible iso-
lates, this target was achieved with all doripenem regimens;
against the doripenem-resistant isolate, only the doripenem Cmax
50-mg/liter regimen achieved this target (Table 2). While a1-log
bacterial kill at 24 h was achieved against the reference strain and
all isolates at both inocula with doripenem Cmax 25- and 50-mg/
liter regimens, this was achieved in only half the cases across both
inocula with the Cmax 2.5-mg/liter regimen (Table 3). Combining
colistin with doripenem produced substantially enhanced bacte-
rial killing at 24 h in 20 out of 24 cases against colistin-susceptible
and -heteroresistant isolates, even with a low index value for each
drug. For example, with the colistin 0.5-mg/liter (fAUC/MIC of
12) plus doripenem Cmax 2.5- or 25-mg/liter (ƒTMIC  35%)
regimen against doripenem-resistant KP032,1-log killing at 24
h occurred in 3 of 4 cases with the combination compared to 3 of
6 cases with equivalent monotherapy (Table 3).
Despite all isolates containing -lactamases, improvements in
bacterial killing over that of equivalent monotherapy were ob-
served across the 72-h duration at both inocula against colistin-
susceptible and -heteroresistant strains. Although enhanced bac-
terial killing was generally present with all combinations, the
killing effect was particularly strong for combinations containing
a doripenem Cmax of 25 mg/liter with colistin dosage regimens of
either 0.5 or 2 mg/liter. That the addition of a doripenem Cmax of
25 mg/liter to low-dosage regimens of colistin (e.g., 0.5 mg/liter)
can substantially improve bacterial killing is an important obser-
vation given that many patients will achieve only low plasma colis-
tin concentrations with currently recommended CMS dosage reg-
imens (17, 43). Encouragingly, improvements in activity with
combination therapy (colistin at 2 mg/liter and a doripenem Cmax
of 25 mg/liter) were also observed against the colistin-resistant
isolate, albeit only with the 106-CFU/ml inoculum.
Previous studies have utilized static time-kill methods to inves-
tigate the combination of a polymyxin (colistin or polymyxin B)
and a carbapenem against K. pneumoniae (8, 16, 23, 41, 46, 49).
While these studies generally reported enhanced activity (usually
reported as synergy) with the combination, only a single, generally
low inoculum (106 CFU/ml) was employed, and experiments
were conducted for no longer than 24 h. Only one study employed
more than one dosage regimen of polymyxin B (41), and impor-
tantly, the emergence of polymyxin resistance (e.g., by using real-
time PAPs) was not reported. To the best of our knowledge, the
present study is the first to investigate polymyxin and carbapenem
combination therapy against K. pneumoniae using an in vitro
PK/PD model and to investigate the emergence of colistin resis-
tance with combination therapy. On only one occasion were colis-
tin-resistant colonies detected following combination therapy for
the colistin-susceptible or -heteroresistant isolates, and this oc-
curred at the high inoculum with the lowest-dosage regimens of
colistin and doripenem (0.5 mg/liter and Cmax at 2.5 mg/liter,
respectively). Although the extensive killing generally observed
against these isolates with the combination regimens complicates
the interpretation of PAPs, on the few occasions where extensive
regrowth (e.g., up to7-log10 CFU/ml) occurred with combina-
tion therapy, no colistin-resistant colonies were detected; the rea-
son for the observed regrowth despite an apparent lack of colistin
resistance is unknown and is under investigation. This important
finding clearly suggests that combining doripenem with colistin
against K. pneumoniae may reduce the emergence of colistin-re-
sistant subpopulations.
As multidrug resistance increases and we await active new
agents, rationally designed combinations of existing antibiotics
are of paramount importance. We have shown for the first time
that clinically relevant dosage regimens of colistin and doripenem
in combination substantially increase bacterial killing against
Deris et al.
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colistin-susceptible, -heteroresistant (and doripenem-resistant),
and colistin-resistant MDR K. pneumoniae and limit the emer-
gence of colistin resistance. Further investigations of colistin com-
binations in animal models and patients are warranted.
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